Spyre Therapeutics (SYRE)
Market Price (7/8/2026): $94.25 | Market Cap: $7.4 BilSector: Health Care | Industry: Biotechnology
Spyre Therapeutics (SYRE)
Market Price (7/8/2026): $94.25Market Cap: $7.4 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Inflammatory Bowel Disease Therapeutics. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.83, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -242 Mil Stock price has recently run up significantly6M Rtn6 month market price return is 211%, 12M Rtn12 month market price return is 516% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.7% Key risksSYRE key risks include [1] intense competition in its target therapeutic area of inflammatory bowel disease (IBD). |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Inflammatory Bowel Disease Therapeutics. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.83, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -242 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 211%, 12M Rtn12 month market price return is 516% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.7% |
| Key risksSYRE key risks include [1] intense competition in its target therapeutic area of inflammatory bowel disease (IBD). |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/7/2026
Spyre Therapeutics (SYRE) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Positive clinical trial data for SPY001 in ulcerative colitis.
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001, an investigational anti-α4β7 antibody for moderate-to-severely active ulcerative colitis, on April 13, 2026. SPY001 achieved its primary endpoint with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score (p<0.0001) and showed clinically meaningful rates of 40% clinical remission and 51% endoscopic improvement.
2. Favorable Phase 2 clinical trial results for SPY002 in ulcerative colitis.
In June 2026, Spyre Therapeutics reported encouraging results from its Phase 2 trial for SPY002, an anti-TL1A candidate, in ulcerative colitis. The trial demonstrated a significant 10.7-point reduction in the Robart's Histopathology Index score (p<0.0001), along with 33% clinical remission and 42% endoscopic improvement. These results were noted as among the highest reported in ulcerative colitis.
Show more
Spyre Therapeutics (SYRE) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Positive clinical trial data for SPY001 in ulcerative colitis.
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001, an investigational anti-α4β7 antibody for moderate-to-severely active ulcerative colitis, on April 13, 2026. SPY001 achieved its primary endpoint with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score (p<0.0001) and showed clinically meaningful rates of 40% clinical remission and 51% endoscopic improvement.
2. Favorable Phase 2 clinical trial results for SPY002 in ulcerative colitis.
In June 2026, Spyre Therapeutics reported encouraging results from its Phase 2 trial for SPY002, an anti-TL1A candidate, in ulcerative colitis. The trial demonstrated a significant 10.7-point reduction in the Robart's Histopathology Index score (p<0.0001), along with 33% clinical remission and 42% endoscopic improvement. These results were noted as among the highest reported in ulcerative colitis.
Show more
Updated on 7/7/2026
Spyre Therapeutics (SYRE) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Positive clinical trial data for SPY001 in ulcerative colitis.
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001, an investigational anti-α4β7 antibody for moderate-to-severely active ulcerative colitis, on April 13, 2026. SPY001 achieved its primary endpoint with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score (p<0.0001) and showed clinically meaningful rates of 40% clinical remission and 51% endoscopic improvement.
2. Favorable Phase 2 clinical trial results for SPY002 in ulcerative colitis.
In June 2026, Spyre Therapeutics reported encouraging results from its Phase 2 trial for SPY002, an anti-TL1A candidate, in ulcerative colitis. The trial demonstrated a significant 10.7-point reduction in the Robart's Histopathology Index score (p<0.0001), along with 33% clinical remission and 42% endoscopic improvement. These results were noted as among the highest reported in ulcerative colitis.
3. Strong analyst consensus and elevated price targets.
Throughout the period, Wall Street analysts maintained a "Strong Buy" consensus rating for SYRE. As of June 30, 2026, 17 analysts polled by S&P Global had an average price target of $100.47, indicating a 15.98% potential upside from the stock price at that time. Some analysts, like David Hoang at Deutsche Bank, issued a price target as high as $135.00 by June 23, 2026, suggesting a 55.8% upside.
4. Strengthened financial position through a substantial capital raise.
In Q2 2026, Spyre Therapeutics completed an underwritten public offering of common stock in April 2026, generating $463 million in gross proceeds. This increased the company's pro forma cash, cash equivalents, and marketable securities to $1.1768 billion as of March 31, 2026, extending its expected cash runway into the second half of 2029.
Show less
Spyre Therapeutics (SYRE) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Positive clinical trial data for SPY001 in ulcerative colitis.
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001, an investigational anti-α4β7 antibody for moderate-to-severely active ulcerative colitis, on April 13, 2026. SPY001 achieved its primary endpoint with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score (p<0.0001) and showed clinically meaningful rates of 40% clinical remission and 51% endoscopic improvement.
2. Favorable Phase 2 clinical trial results for SPY002 in ulcerative colitis.
In June 2026, Spyre Therapeutics reported encouraging results from its Phase 2 trial for SPY002, an anti-TL1A candidate, in ulcerative colitis. The trial demonstrated a significant 10.7-point reduction in the Robart's Histopathology Index score (p<0.0001), along with 33% clinical remission and 42% endoscopic improvement. These results were noted as among the highest reported in ulcerative colitis.
3. Strong analyst consensus and elevated price targets.
Throughout the period, Wall Street analysts maintained a "Strong Buy" consensus rating for SYRE. As of June 30, 2026, 17 analysts polled by S&P Global had an average price target of $100.47, indicating a 15.98% potential upside from the stock price at that time. Some analysts, like David Hoang at Deutsche Bank, issued a price target as high as $135.00 by June 23, 2026, suggesting a 55.8% upside.
4. Strengthened financial position through a substantial capital raise.
In Q2 2026, Spyre Therapeutics completed an underwritten public offering of common stock in April 2026, generating $463 million in gross proceeds. This increased the company's pro forma cash, cash equivalents, and marketable securities to $1.1768 billion as of March 31, 2026, extending its expected cash runway into the second half of 2029.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 86.8% change in SYRE stock from 3/31/2026 to 7/7/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 50.44 | 94.23 | 86.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 74 | 79 | -5.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/7/2026| Return | Correlation | |
|---|---|---|
| SYRE | 86.8% | |
| Market (SPY) | 15.0% | 32.4% |
| Sector (XLV) | 12.2% | 8.5% |
Fundamental Drivers
The 187.6% change in SYRE stock from 12/31/2025 to 7/7/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.76 | 94.23 | 187.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 61 | 79 | -22.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/7/2026| Return | Correlation | |
|---|---|---|
| SYRE | 187.6% | |
| Market (SPY) | 9.9% | 35.0% |
| Sector (XLV) | 6.7% | 19.6% |
Fundamental Drivers
The 529.5% change in SYRE stock from 6/30/2025 to 7/7/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302025 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.97 | 94.23 | 529.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 60 | 79 | -23.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/7/2026| Return | Correlation | |
|---|---|---|
| SYRE | 529.5% | |
| Market (SPY) | 22.0% | 34.7% |
| Sector (XLV) | 23.6% | 26.5% |
Fundamental Drivers
The 736.7% change in SYRE stock from 6/30/2023 to 7/7/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.26 | 94.23 | 736.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | |
| P/S Multiple | 36.5 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 4 | 79 | -95.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/7/2026| Return | Correlation | |
|---|---|---|
| SYRE | 736.7% | |
| Market (SPY) | 74.6% | 32.6% |
| Sector (XLV) | 29.7% | 27.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SYRE Return | -40% | -91% | 91% | 8% | 41% | 171% | -55% |
| Peers Return | 36% | 21% | 2% | 8% | 26% | 15% | 161% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| SYRE Win Rate | 42% | 42% | 50% | 67% | 50% | 57% | |
| Peers Win Rate | 62% | 62% | 43% | 47% | 60% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| SYRE Max Drawdown | -59% | -93% | -83% | -50% | -52% | -14% | |
| Peers Max Drawdown | -16% | -18% | -23% | -21% | -22% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRK, ABBV, LLY, JNJ, PFE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/7/2026 (YTD)
How Low Can It Go
| Event | SYRE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.3% | -18.8% |
| % Gain to Breakeven | 89.6% | 23.1% |
| Time to Breakeven | 192 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.8% | -7.8% |
| % Gain to Breakeven | 14.7% | 8.5% |
| Time to Breakeven | 16 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.8% | -9.5% |
| % Gain to Breakeven | 55.7% | 10.5% |
| Time to Breakeven | 20 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -79.5% | -6.7% |
| % Gain to Breakeven | 388.7% | 7.1% |
| Time to Breakeven | 15 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -57.3% | -33.7% |
| % Gain to Breakeven | 134.2% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.1% | -19.2% |
| % Gain to Breakeven | 56.5% | 23.8% |
| Time to Breakeven | 546 days | 105 days |
In The Past
Spyre Therapeutics's stock fell -47.3% during the 2025 US Tariff Shock. Such a loss loss requires a 89.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SYRE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.3% | -18.8% |
| % Gain to Breakeven | 89.6% | 23.1% |
| Time to Breakeven | 192 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.8% | -9.5% |
| % Gain to Breakeven | 55.7% | 10.5% |
| Time to Breakeven | 20 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -79.5% | -6.7% |
| % Gain to Breakeven | 388.7% | 7.1% |
| Time to Breakeven | 15 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -57.3% | -33.7% |
| % Gain to Breakeven | 134.2% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.1% | -19.2% |
| % Gain to Breakeven | 56.5% | 23.8% |
| Time to Breakeven | 546 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -51.5% | -3.7% |
| % Gain to Breakeven | 106.2% | 3.9% |
| Time to Breakeven | 221 days | 6 days |
In The Past
Spyre Therapeutics's stock fell -47.3% during the 2025 US Tariff Shock. Such a loss loss requires a 89.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Spyre Therapeutics (SYRE)
Spyre Therapeutics, as described in the provided context, is a clinical-stage biotechnology company that specializes in designing and developing human enzyme therapeutics. The company's core mission is to address the needs of patients and families suffering from rare metabolic diseases, focusing on conditions where current treatment options may be limited or inadequate.
The company's primary product candidates include pegzilarginase, a recombinant human Arginase 1 currently in a Phase III trial to evaluate its safety and efficacy for Arginase 1 deficiency. Another key therapeutic in its pipeline is AGLE-177, a polyethylene glycol modified compound progressing through Phase I/II clinical trials for the treatment of homocystinuria. Additionally, Spyre Therapeutics maintains a preclinical pipeline, which features AGLE-325 for cystinuria, along with other research initiatives aimed at broadening its therapeutic scope within rare metabolic disorders.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Cameron Turtle, Chief Executive Officer
Cameron Turtle was appointed CEO of Spyre Therapeutics in November 2023, after serving as the company's Chief Operating Officer since June 2023. He has experience in building, financing, and shaping biopharma organizations from preclinical development to commercialization. Prior to Spyre, he was a Venture Partner at Foresite Labs and the Chief Strategy Officer of BridgeBio Pharma, Inc. He also served as Chief Business Officer of Eidos Therapeutics, where he was responsible for business development, investor relations, and various operational functions. Before his roles in biotech, Dr. Turtle was a consultant at McKinsey & Company, advising pharmaceutical and medical device companies on M&A, growth strategy, clinical trial strategy, and sales force optimization. He holds a B.S. in Bioengineering from the University of Washington and a D. Phil. in Cardiovascular Medicine from the University of Oxford. Dr. Turtle is a Rhodes Scholar, Goldwater Scholar, and a Forbes 30 Under 30 awardee. He has held ownership stakes in BridgeBio Pharma Inc. and Eidos Therapeutics Inc.
Scott L. Burrows, Chief Financial Officer
Scott L. Burrows is a seasoned biopharma industry professional with over two decades of experience in finance. Before joining Spyre, he served as Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he played a key role in the company's initial public offering, subsequent equity and debt financings, and its transition to a commercial-stage entity. Mr. Burrows also held the position of Head of International Investor Relations for Shire, plc. He spent 15 years at Amgen, Inc. in various financial planning and analysis, treasury, and investor relations roles. He began his career as a consultant at Arthur Andersen. Mr. Burrows earned his B.A. and M.B.A. from the University of California, Los Angeles.
Heidy Abreu King-Jones, Chief Legal Officer and Corporate Secretary
Heidy Abreu King-Jones serves as the Chief Legal Officer and Corporate Secretary for Spyre Therapeutics.
Sheldon Sloan, Chief Medical Officer
Sheldon Sloan is the Chief Medical Officer at Spyre Therapeutics.
Brian Connolly, Chief Technical Officer
Brian Connolly holds the position of Chief Technical Officer at Spyre Therapeutics.
AI Analysis | Feedback
Here are the key risks to Spyre Therapeutics (SYRE):
- Reliance on Successful Clinical Development and Regulatory Approval: As a clinical-stage biotechnology company, Spyre Therapeutics' future success is heavily dependent on the successful development, clinical trial outcomes, and regulatory approval of its pipeline candidates, such as SPY001, SPY002, and SPY003. The inherent risks of drug development, including potential delays, increased costs, and the failure to demonstrate efficacy and safety in trials, could significantly impact the company's prospects, as it currently generates no revenue from product sales. There is no guarantee that its product candidates will receive the necessary regulatory approvals to reach the market.
- Intense Competition: The biotechnology sector, particularly in the inflammatory bowel disease (IBD) and immune-mediated disease areas, is highly competitive. Spyre Therapeutics faces significant competition from both established pharmaceutical companies (such as AbbVie with Humira and Skyrizi, and Takeda with Entyvio) and other biotech firms developing similar therapies. This competitive landscape could impact Spyre's market share and pricing power if rivals introduce comparable or superior products more quickly or efficiently. Additionally, concerns around high immunogenicity rates associated with prior bispecific antibodies could hinder its ability to compete effectively against alternatives with lower immunogenicity.
- Funding and Market Access Challenges: While Spyre Therapeutics has reported a robust cash position providing a runway into the second half of 2028, as a clinical-stage company with ongoing research and development costs and no current product revenue, there is a risk of high cash burn. This could necessitate the need for additional capital in the future, potentially leading to further equity dilution for existing shareholders. Furthermore, even with regulatory approval, challenges related to market access and reimbursement could limit the commercial potential and adoption of its product candidates.
AI Analysis | Feedback
null
AI Analysis | Feedback
Spyre Therapeutics (NASDAQ: SYRE) is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases.
The company's pipeline includes investigational extended half-life antibodies targeting α4β7 (SPY001), TL1A (SPY002, SPY072), and IL-23 (SPY003), as well as combination therapies (SPY120, SPY130, SPY230) for IBD. SPY072 is also being evaluated for rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).
The addressable markets for Spyre Therapeutics' main products and services are:
- Inflammatory Bowel Disease (IBD): The global inflammatory bowel disease treatment market size was valued at approximately USD 22.38 billion in 2025 and is projected to reach around USD 32.46 billion by 2035, with a compound annual growth rate (CAGR) of 3.79% from 2026 to 2035. Another estimate places the global IBD treatment market at USD 24.1 billion in 2025, growing to USD 42.0 billion by 2035 at a CAGR of 5.7%. North America is anticipated to be a leading market for IBD, with a market size of USD 12.72 billion in 2025.
- Crohn's Disease: The global Crohn's disease treatment market size is estimated to reach USD 14.4 billion in 2026 and is projected to reach USD 19.2 billion by 2033, growing at a CAGR of 4.2% between 2026 and 2033. In 2024, the global Crohn's disease market size was valued at USD 10.21 billion and is expected to reach USD 13.65 billion by 2032, at a CAGR of 3.70%. The United States accounted for the highest market size of Crohn's disease, approximately USD 8,000 million in 2024, and is expected to increase at a CAGR of 4.5%.
- Ulcerative Colitis: The global ulcerative colitis market size was valued at USD 6.59 billion in 2024 and is expected to reach USD 9.72 billion by 2033, growing at a CAGR of 6.7% during the forecast period. Another report indicates the global ulcerative colitis market size is estimated to be valued at USD 8.70 billion in 2026 and is expected to reach USD 15.30 billion by 2033, exhibiting a CAGR of 8.5% from 2026 to 2033. The market size for ulcerative colitis in the 7MM (United States, EU4 countries, United Kingdom, and Japan) was approximately USD 8,400 million in 2023. The USA market for ulcerative colitis was approximately USD 5,900 million in 2023.
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Axial Spondyloarthritis (axSpA): While specific market sizes for these individual rheumatic diseases directly linked to Spyre's pipeline were not explicitly detailed in the provided search results, Spyre Therapeutics is developing SPY072 for these conditions. The broader inflammatory bowel disease market is fueled by the prevalence of Crohn's disease and ulcerative colitis, which affected around 5 million and nearly 5 million individuals globally in 2023 and 2019, respectively.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Spyre Therapeutics (SYRE) over the next 2-3 years:
- Successful Clinical Development and Commercialization of Lead IBD Programs (SPY001, SPY002, SPY003, and Combinations): Spyre Therapeutics is a clinical-stage biotechnology company with a pipeline of extended half-life antibodies aimed at treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company's lead product candidates, SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23), along with their combination therapies (SPY120, SPY130, SPY230), are currently in Phase 2 clinical trials. Initial proof-of-concept readouts from the SKYLINE Phase 2 platform trial in ulcerative colitis are anticipated to begin in the second quarter of 2026. Positive results and subsequent advancement towards commercialization for these programs would be the primary driver of future revenue.
- Expansion into Rheumatic Diseases with SPY072: Spyre Therapeutics is also expanding its focus beyond IBD into the market for rheumatic diseases. The company is developing SPY072, a distinct extended half-life anti-TL1A monoclonal antibody, for the potential treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Phase 2 trial readouts for SPY072 from the SKYWAY basket trial across all these indications are expected in the fourth quarter of 2026. Successful development and eventual market entry in these additional indications would open up new significant revenue streams.
- Differentiation Through Best-in-Class Antibody Engineering and Convenient Dosing: Spyre Therapeutics aims to create "next-generation" therapies by utilizing advanced antibody engineering to develop extended half-life antibodies. This technology is designed to enable infrequent dosing, potentially on a quarterly or twice-annual basis, offering improved convenience and potentially superior efficacy compared to existing treatments. If successful in clinical trials, this differentiated profile could provide a significant competitive advantage and drive market adoption, thereby contributing to future revenue growth.
AI Analysis | Feedback
Share Issuance
- In June 2023, Aeglea BioTherapeutics completed a stock-for-stock acquisition of the privately held Spyre Therapeutics, Inc., where Spyre equity was converted into Aeglea common stock and Series A preferred stock, with Aeglea shareholders owning just under 5.5% of the combined company.
- Concurrently with the June 2023 acquisition, the company entered into an oversubscribed private investment in public equity (PIPE) for approximately $210 million in gross proceeds.
- In December 2023, Spyre Therapeutics announced a private placement (PIPE) financing expected to result in gross proceeds of approximately $180 million, through the sale of 6,000,000 shares of common stock at $15.00 per share and 150,000 shares of Series B non-voting convertible preferred stock at $600.00 per share.
- In October 2025, Spyre Therapeutics closed an underwritten public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters' option, at $18.50 per share, generating approximately $316.2 million in gross proceeds.
Inbound Investments
- A $210 million private financing, led by Fairmount Funds Management and joined by more than a dozen other blue-chip investors, was secured concurrently with the merger in June 2023.
- A December 2023 private placement of $180 million included participation from new and existing investors such as Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, and Braidwell.
Outbound Investments
- Aeglea BioTherapeutics, before becoming Spyre Therapeutics, had not made any investments or acquisitions.
Capital Expenditures
- Spyre Therapeutics reported $0.00 in capital expenditures for the years 2021, 2022, and 2023.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 191.75 |
| Mkt Cap | 384.6 |
| Rev LTM | 64,541 |
| Op Inc LTM | 18,176 |
| FCF LTM | 12,242 |
| FCF 3Y Avg | 11,334 |
| CFO LTM | 19,185 |
| CFO 3Y Avg | 14,679 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.9% |
| Rev Chg 3Y Avg | 4.4% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 11.9% |
| Op Inc Chg 3Y Avg | 39.8% |
| Op Mgn LTM | 26.8% |
| Op Mgn 3Y Avg | 25.6% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 27.2% |
| CFO/Rev 3Y Avg | 26.2% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 20.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of biopharmaceutical products for the treatment of patients with inflammatory bowel disease (IBD) | 0 | 0 | 1 | ||
| Development fee and royalty | 2 | 7 | |||
| License | 0 | 12 | |||
| Total | 0 | 0 | 1 | 2 | 19 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development of biopharmaceutical products for the treatment of patients with inflammatory bowel disease (IBD) | -155 | -208 | -339 |
| Total | -155 | -208 | -339 |
| $ Mil | 2021 | 2020 | 2019 |
|---|---|---|---|
| Single Segment | 110 | 162 | 83 |
| Total | 110 | 162 | 83 |
Price Behavior
Price Behavior
| Market Price | $94.23 | |
| Market Cap ($ Bil) | 7.4 | |
| First Trading Date | 04/07/2016 | |
| Distance from 52W High | -6.1% | |
| 50 Days | 200 Days | |
| DMA Price | $76.53 | $44.63 |
| DMA Trend | up | up |
| Distance from DMA | 23.1% | 111.1% |
| 3M | 1YR | |
| Volatility | 80.4% | 69.8% |
| Downside Capture | 108.61 | 91.86 |
| Upside Capture | 282.31 | 287.66 |
| Correlation (SPY) | 36.2% | 35.7% |
SYRE Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.34 | 1.54 | 2.20 | 1.80 | 1.93 | 1.64 |
| Up Beta | 3.10 | 3.25 | 2.88 | 3.20 | 2.92 | 1.70 |
| Down Beta | 2.89 | 0.95 | 1.05 | -0.05 | 1.11 | 1.70 |
| Up Capture | 169% | 189% | 382% | 476% | 724% | 973% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 20 | 35 | 67 | 135 | 388 |
| Down Capture | -59% | 91% | 136% | 90% | 96% | 106% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 21 | 28 | 58 | 116 | 360 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYRE | |
|---|---|---|---|---|
| SYRE | 520.4% | 69.8% | 2.90 | - |
| Sector ETF (XLV) | 23.0% | 15.7% | 1.13 | 26.2% |
| Equity (SPY) | 20.7% | 12.5% | 1.22 | 34.7% |
| Gold (GLD) | 23.0% | 27.8% | 0.73 | 16.1% |
| Commodities (DBC) | 22.9% | 18.6% | 0.97 | -6.3% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 20.9% |
| Bitcoin (BTCUSD) | -41.8% | 42.8% | -1.14 | 23.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYRE | |
|---|---|---|---|---|
| SYRE | -12.5% | 179.0% | 0.41 | - |
| Sector ETF (XLV) | 7.1% | 14.9% | 0.29 | 10.8% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 10.6% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | -0.0% |
| Commodities (DBC) | 7.6% | 19.5% | 0.29 | -6.0% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 5.6% |
| Bitcoin (BTCUSD) | 13.2% | 53.5% | 0.43 | 2.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYRE | |
|---|---|---|---|---|
| SYRE | -3.3% | 136.1% | 0.38 | - |
| Sector ETF (XLV) | 10.9% | 16.6% | 0.54 | 14.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 16.3% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 1.1% |
| Commodities (DBC) | 6.2% | 18.0% | 0.27 | 0.3% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 11.4% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 4.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 2.7% | 10.6% | 6.4% |
| 2/19/2026 | 14.3% | 14.1% | 9.1% |
| 11/4/2025 | -0.6% | 1.6% | 45.6% |
| 8/5/2025 | -5.4% | -5.8% | 0.7% |
| 5/8/2025 | 9.6% | 13.1% | 33.4% |
| 2/27/2025 | 7.2% | 11.6% | -2.3% |
| 11/7/2024 | 5.0% | -17.0% | -28.9% |
| 8/7/2024 | 2.9% | 0.7% | 13.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 15 | 16 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 4.9% | 7.4% | 8.8% |
| Median Negative | -3.0% | -8.0% | -24.5% |
| Max Positive | 14.3% | 41.6% | 90.6% |
| Max Negative | -6.6% | -18.9% | -60.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | 2.7% | 10.6% | 6.4% |
| 2/19/2026 | 14.3% | 14.1% | 9.1% |
| 11/4/2025 | -0.6% | 1.6% | 45.6% |
| 8/5/2025 | -5.4% | -5.8% | 0.7% |
| 5/8/2025 | 9.6% | 13.1% | 33.4% |
| 2/27/2025 | 7.2% | 11.6% | -2.3% |
| 11/7/2024 | 5.0% | -17.0% | -28.9% |
| 8/7/2024 | 2.9% | 0.7% | 13.9% |
| 5/9/2024 | 4.9% | 7.4% | 3.7% |
| 2/29/2024 | 9.0% | 41.6% | 34.8% |
| 11/9/2023 | 0.2% | 5.5% | 90.6% |
| 8/11/2023 | -4.7% | -9.1% | 7.1% |
| 4/25/2023 | 0.9% | 5.3% | -10.2% |
| 3/2/2023 | -1.3% | 5.8% | -26.4% |
| 11/3/2022 | -6.6% | 6.6% | -59.0% |
| 8/4/2022 | 6.4% | 18.5% | 36.3% |
| 5/5/2022 | 1.3% | -13.5% | -60.0% |
| 3/8/2022 | 3.9% | -18.9% | 8.6% |
| 11/4/2021 | -1.0% | -8.0% | -22.5% |
| 8/5/2021 | 3.2% | -1.7% | 12.9% |
| 5/10/2021 | -2.8% | 4.4% | -6.1% |
| 3/18/2021 | -3.6% | -5.4% | 5.3% |
| 11/5/2020 | 8.1% | 24.1% | 3.5% |
| 8/10/2020 | -3.0% | -4.7% | 4.7% |
| SUMMARY STATS | |||
| # Positive | 15 | 15 | 16 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 4.9% | 7.4% | 8.8% |
| Median Negative | -3.0% | -8.0% | -24.5% |
| Max Positive | 14.3% | 41.6% | 90.6% |
| Max Negative | -6.6% | -18.9% | -60.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/18/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 08/06/2019 | 10-Q |
Insider Activity
Updated 7/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 7022026 | 87.74 | 7,500 | 658,040 | 8,597,856 | Form |
| 2 | Sloan, Sheldon | Chief Medical Officer | Direct | Sell | 7022026 | 87.70 | 8,334 | Form | ||
| 3 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 7022026 | 87.69 | 15,000 | 1,315,346 | 51,082,794 | Form |
| 4 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 6262026 | 87.13 | 15,000 | 1,307,000 | 8,538,544 | Form |
| 5 | Fairmount, Funds Management Llc | Fairmount Healthcare Fund II L.P. | Sell | 6232026 | 85.31 | 4,684,781 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 7022026 | 87.74 | 7,500 | 658,040 | 8,597,856 | Form |
| 2 | Sloan, Sheldon | Chief Medical Officer | Direct | Sell | 7022026 | 87.70 | 8,334 | Form | ||
| 3 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 7022026 | 87.69 | 15,000 | 1,315,346 | 51,082,794 | Form |
| 4 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 6262026 | 87.13 | 15,000 | 1,307,000 | 8,538,544 | Form |
| 5 | Fairmount, Funds Management Llc | Fairmount Healthcare Fund II L.P. | Sell | 6232026 | 85.31 | 4,684,781 | Form | |||
| 6 | Henderson, Michael Thomas | Direct | Sell | 6232026 | 100.00 | 20,000 | 2,000,000 | 6,860,600 | Form | |
| 7 | Sloan, Sheldon | Chief Medical Officer | Direct | Sell | 6032026 | 75.00 | 8,333 | Form | ||
| 8 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 6032026 | 70.43 | 15,000 | 1,056,486 | 42,086,177 | Form |
| 9 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 6032026 | 71.06 | 7,500 | 532,937 | 6,963,284 | Form |
| 10 | Henderson, Michael Thomas | Direct | Sell | 5082026 | 74.40 | 80,000 | 5,952,050 | 6,592,342 | Form | |
| 11 | Sloan, Sheldon | Chief Medical Officer | Direct | Sell | 5012026 | 71.50 | 78,333 | Form | ||
| 12 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 5012026 | 71.37 | 12,500 | 892,125 | 6,993,832 | Form |
| 13 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 5012026 | 71.37 | 15,000 | 1,070,507 | 43,715,224 | Form |
| 14 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 4032026 | 49.33 | 15,000 | 739,912 | 30,954,972 | Form |
| 15 | Sloan, Sheldon | Chief Medical Officer | Direct | Sell | 4032026 | 50.00 | 7,958 | Form | ||
| 16 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 4032026 | 49.34 | 7,500 | 370,076 | 4,835,364 | Form |
| 17 | Burrows, Scott L | Chief Financial Officer | Direct | Sell | 3032026 | 40.65 | 2,500 | 101,620 | 3,983,260 | Form |
| 18 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 3032026 | 42.19 | 15,000 | 632,866 | 27,109,448 | Form |
| 19 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 2042026 | 32.80 | 15,000 | 492,045 | 21,569,291 | Form |
| 20 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 1062026 | 30.68 | 15,000 | 460,134 | 20,611,156 | Form |
| 21 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 12032025 | 29.02 | 15,000 | 435,356 | 19,936,583 | Form |
| 22 | Turtle, Cameron | Chief Executive Officer | Direct | Sell | 11052025 | 23.33 | 45,000 | 1,049,778 | 16,374,365 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/7/2026